Draximage takes skeletal imaging agent to the US:
This article was originally published in Clinica
Executive Summary
Draximage has launched in the US a new formulation of a skeletal imaging agent for pinpointing areas of altered osteogenesis or bone growth. MDP-25 (99mTc-methylene diphosphonic acid kit), when used with gamma camera imaging, allows doctors to detect areas of abnormal osteogenesis, which show altered uptake, making it possible to visualise a variety of bone lesions. It is used in the assessment of metastatic bone disease, Paget's disease, arthritic disease and osteomyelitis. The new formulation produces more effective images of the extremities of the skeleton, particularly hands and feet, claims the company, a subsidiary of Mississauga, Ontario-based Draxis Health.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.